Form 4: Tarsus Pharmaceuticals Executive Receives Stock Options and Restricted Stock Units

Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, was granted stock options and restricted stock units (RSUs) on March 7, 2024, according to a Form 4 filing with the SEC.

Summary

• Aziz Mottiwala, the Chief Commercial Officer of Tarsus Pharmaceuticals, received stock options and restricted stock units (RSUs) on March 7, 2024.
• The stock options grant consists of 47,500 shares with an exercise price of $35.50.
• These options vest over four years, with 25% vesting on March 7, 2025, and the remaining 75% vesting monthly over the subsequent three years, contingent upon continuous service.
• Mottiwala also received 32,079 RSUs, each representing a contingent right to receive one share of Tarsus Pharmaceuticals' common stock.
• The RSUs vest in four equal installments of 25% on March 15th of each year from 2025 to 2028, subject to continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the executive's continued contribution.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.
• The vesting schedules encourage continued service and commitment to the company over the next four years.

Future Outlook

The vesting schedules for both the stock options and RSUs are contingent upon the Reporting Person's continuous service, suggesting an expectation of continued employment and contribution to the company's success.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to attract, retain, and incentivize key executives. The specific terms of the grants, such as vesting schedules and exercise prices, are tailored to the company's specific circumstances and strategic goals.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation tools for executives in publicly traded pharmaceutical companies.
• Vesting schedules of 3-4 years are typical to ensure long-term alignment with company performance.
• Companies like Alcon and Bausch + Lomb also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with long-term value creation.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates